Cancer patients in Minnesota's medical cannabis program reported significant symptom improvement across the board

Significant reductions were found across all 8 symptoms (anxiety, appetite loss, depression, sleep disturbance, fatigue, nausea, pain, and vomiting) within 4 months of starting medical cannabis. The proportion achieving 30% or greater symptom reduction ranged from 27% (fatigue) to 50% (vomiting). Adverse effects were reported by only 10.5% of patients.

Observational study using patient-reported symptom scores collected routinely by Minnesota's medical cannabis program. Patients rated 8 symptoms at their worst in the last 24 hours before each purchase. Baseline scores were compared with averages over the first 4 months.

Minnesota's program is unique in routinely collecting standardized symptom data, providing real-world evidence on medical cannabis outcomes in cancer patients at a scale that individual clinical trials rarely achieve.

This is among the largest real-world datasets on medical cannabis for cancer symptoms. The broad symptom improvement and low adverse effect rate support the tolerability argument, though the lack of a control group limits causal conclusions.

No control group or randomization. Symptom improvement could reflect placebo effect, disease progression, or concurrent treatments. Self-reported data before purchases may reflect selection bias (patients who benefit keep purchasing). Drop-out bias not addressed.